期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
前列腺素E_1治疗肝硬化对IL-1β、IL-6、IL-8、TNFα-的影响 被引量:7
1
作者 李刚 陈金春 +2 位作者 付荣权 马志全 陈海斌 《海峡药学》 2012年第6期73-75,共3页
目的研究前列腺素E1治疗肝硬化对IL-1β、IL-6、IL-8、TNFα-的影响。方法选择符合诊断标准的乙型肝炎肝硬化患者78例,分对照组32例,治疗组46例;对照组用复方丹参30mL+阿拓莫兰0.2g+门冬氨酸钾镁30mL分别加入5%GNS 250mL静滴,1日1次;治... 目的研究前列腺素E1治疗肝硬化对IL-1β、IL-6、IL-8、TNFα-的影响。方法选择符合诊断标准的乙型肝炎肝硬化患者78例,分对照组32例,治疗组46例;对照组用复方丹参30mL+阿拓莫兰0.2g+门冬氨酸钾镁30mL分别加入5%GNS 250mL静滴,1日1次;治疗组加用前列腺素E1100μg+10%GS 250mL静滴,1日1次;疗程均为2个月;观察两组临床有效率及对及对IL-1β、IL-6、IL-8、TNFα-的影响,并进行统计分析。结果两组有效率分别为28.13%和69.57%,两者间比较差异显著(P<0.05);两组治疗前和治疗后的及对IL-1β、IL-6、IL-8、TNFα-值分别为,两组治疗前后及治疗后间比较均有显著差异(P<0.05);结论前列腺素E1治疗肝硬化疗效显著,可能与PGE1可减少IL-1β、IL-6、IL-8、TNF-α等促炎性细胞因子的释放,抑制炎症反应,改善微循环,减少胶原纤维的合成或释放,缓解肝纤维化进程,提高肝细胞的代谢能力等有关。 展开更多
关键词 前列腺素E1(ProstaglandinEl PGE1) 肝硬化(hepaticcirrhosis) IL-1Β IL-6 IL-8 TNF-α
在线阅读 下载PDF
Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress 被引量:12
2
作者 Balasubramaniyan Vairappan 《World Journal of Hepatology》 CAS 2015年第3期443-459,共17页
This review describes the recent developments in the pathobiology of endothelial dysfunction(ED) in the context of cirrhosis with portal hypertension and defines novel strategies and potential targets for therapy. ED ... This review describes the recent developments in the pathobiology of endothelial dysfunction(ED) in the context of cirrhosis with portal hypertension and defines novel strategies and potential targets for therapy. ED has prognostic implications by predicting unfavourable early hepatic events and mortality in patients with portal hypertension and advanced liver diseases. EDcharacterised by an impaired bioactivity of nitric oxide(NO) within the hepatic circulation and is mainly due to decreased bioavailability of NO and accelerated degradation of NO with reactive oxygen species. Furthermore, elevated inflammatory markers also inhibit NO synthesis and causes ED in cirrhotic liver. Therefore, improvement of NO availability in the hepatic circulation can be beneficial for the improvement of endothelial dysfunction and associated portal hypertension in patients with cirrhosis. Furthermore, therapeutic agents that are identified in increasing NO bioavailability through improvement of hepatic endothelial nitric oxide synthase(e NOS) activity and reduction in hepatic asymmetric dimethylarginine, an endogenous modulator of e NOS and a key mediator of elevated intrahepatic vascular tone in cirrhosis would be interesting therapeutic approaches in patients with endothelial dysfunction and portal hypertension in advanced liver diseases. 展开更多
关键词 Asymmetric DIMETHYLARGININE Endothelialfunction NITRIC oxide PORTAL HYPERTENSION hepaticcirrhosis Reactive oxygen species INFLAMMATION
在线阅读 下载PDF
Professor LV Wenliang's experience in the treatment of liver cirrhosis
3
作者 Shuang Liu Wen-Liang Lv 《Journal of Hainan Medical University》 2020年第22期53-57,共5页
Professor Lv Wenliang believes that cirrhosis is a disease of the essence of vacuity and evil,and the patient suffers from vacuity and poison stasis for a long time.Is Yin and Yang but turbulent,qi and blood disorder,... Professor Lv Wenliang believes that cirrhosis is a disease of the essence of vacuity and evil,and the patient suffers from vacuity and poison stasis for a long time.Is Yin and Yang but turbulent,qi and blood disorder,liver and spleen is not consistent.Therefore,when the temporary syndrome from the Yin system Yang,to its outline;Adjust the air and blood to tamp the base;The liver and spleen should be dredged and the spleen should be regulated in accordance with its nature.Based on this objective,this paper discusses the clinical method of treating cirrhosis of liver by professor LV,so as to know its inverse,its shield and its life. 展开更多
关键词 hepaticcirrhosis Lv Wenliang EXPERIENCE
在线阅读 下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部